<DOC>
	<DOC>NCT02049138</DOC>
	<brief_summary>This is a Phase 2, multicenter, open-label extension study in RA subjects.</brief_summary>
	<brief_title>An Open-label Extension Study Evaluating the Safety and Efficacy of ABT-494 in Rheumatoid Arthritis Subjects</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>1. Subjects who have completed Study M13550 or Study M13537 with ABT494 and has not developed any discontinuation criteria. 2. If the subject has evidence of new latent Tuberculosis (TB) infection, the subject must initiate and complete a minimum of 2 weeks (or per local guidelines, whichever is longer) of an ongoing TB prophylaxis before continuing to receive study drug. 3. If female, subject must meet one of the following criteria: Postmenopausal (defined as no menses for at least 1 year). Surgically sterile (bilateral oophorectomy or hysterectomy). Practicing from the time of screening until at least 30 days after the last dose of study drug at least TWO of the following methods of birth control: 1. Tubal ligation 2. Partner vasectomy (at least 6 months earlier) (the vasectomized male partner should be the sole partner for that female subject) 3. Intrauterine device 4. A male condom with spermicidal jelly or cream 5. Diaphragm, contraceptive sponge or cervical cap with spermicidal jelly or cream 6. Hormonal contraceptives (injected, oral, transdermal or implanted methods) must have been taking at least 2 months prior to dosing 4. Male subjects must agree to follow protocolspecified pregnancy avoidance measures, including refraining from donating sperm, for up to 30 days post last dose of study drug. 5. Subjects must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study specific procedures. 1. Pregnant or breastfeeding female. 2. Ongoing infections at Week 0 that have NOT been successfully treated. Subjects with ongoing infections undergoing treatment may be enrolled BUT NOT dosed until the infection has been successfully treated. 3. Anticipated requirement or receipt of any live vaccine during study participation including up to 30 days after the last dose of study drug. 4. Laboratory values from the visit immediately prior to Baseline Visit meeting the following criteria: Serum aspartate transaminase (AST) or alanine transaminase (ALT) &gt; 3.0 × Upper Limit of Normal (ULN) Estimated glomerular filtration rate by simplified 4variable Modification of Diet in Renal Disease (MDRD) formula &lt; 40mL/min/1.73m2 Total white blood cell count (WBC) &lt; 2,000/μL Absolute neutrophil count (ANC) &lt; 1,000/μL Platelet count &lt; 50,000/μL Absolute lymphocytes count &lt; 500/μL Hemoglobin &lt; 8 gm/dL 5. Enrollment in another interventional clinical study while participating in this study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Joint Diseases</keyword>
	<keyword>Musculoskeletal Disease</keyword>
	<keyword>Anti-inflammatory Agents</keyword>
	<keyword>Antirheumatic agents</keyword>
	<keyword>Arthritis</keyword>
</DOC>